ZOM · Zomedica Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.80M | - | $8.10M | $6.96M | $6.50M | - | $7.00M | $6.13M | $6.26M | - |
| Cost of Revenue | $3.31M | - | $2.66M | $2.30M | $2.09M | - | $1.94M | $1.77M | $2.15M | - |
| Gross Profit | $5.48M | - | $5.44M | $4.67M | $4.41M | - | $5.06M | $4.36M | $4.12M | - |
| R&D | $1.15M | - | $1.78M | $1.89M | $1.85M | - | $1.84M | $1.51M | $1.77M | - |
| SG&A | $5.41M | - | $5.90M | $6.16M | $6.26M | - | $6.76M | $6.85M | $8.63M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $519.0K | - | $506.0K | $509.0K | $521.0K | - | $417.0K | $351.0K | $334.0K | - |
| Operating Income | ($4.90M) | - | ($6.61M) | ($8.04M) | ($64.55M) | - | ($7.44M) | ($25.07M) | ($10.39M) | - |
| Interest Expense | - | - | - | - | - | - | $64.0K | $62.0K | - | - |
| Income Tax | $39.0K | - | ($19.0K) | $12.0K | ($57.0K) | - | ($27.0K) | ($143.0K) | ($166.0K) | - |
| Net Income | ($4.53M) | - | ($6.12M) | ($7.40M) | ($63.81M) | - | ($6.70M) | ($23.93M) | ($9.16M) | - |
| EPS - Basic | $0.00 | - | ($0.01) | ($0.01) | ($0.07) | - | ($0.01) | ($0.02) | ($0.01) | - |
| EPS - Diluted | $0.00 | - | ($0.01) | ($0.01) | ($0.07) | - | ($0.01) | ($0.02) | ($0.01) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.37M | $9.02M | $7.50M | $8.13M | $8.84M | $7.02M | $9.75M | $7.94M | $10.94M | $12.95M |
| Accounts Receivable | $4.43M | $3.01M | $3.14M | $2.30M | $1.57M | $2.42M | $1.76M | $1.38M | $1.65M | $1.20M |
| Inventory | $5.88M | $5.54M | $5.52M | $5.67M | $5.36M | $5.06M | $5.43M | $5.51M | $5.06M | $5.12M |
| Accounts Payable | $2.20M | $1.72M | $1.65M | $2.07M | $2.29M | $1.93M | $2.38M | $2.32M | - | - |
| Current Assets | $60.03M | $64.04M | $64.69M | $68.60M | $73.22M | $81.77M | $87.27M | $89.22M | $92.07M | $99.88M |
| Total Assets | $121.53M | $127.04M | $130.91M | $136.47M | $142.99M | $207.36M | $214.12M | $219.88M | $243.70M | $253.20M |
| Current Liabilities | $8.56M | $9.45M | $8.43M | $8.13M | $7.41M | $9.33M | $8.06M | $7.83M | $8.01M | $9.03M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $10.59M | $11.64M | $11.22M | $11.12M | $10.55M | $11.70M | $11.27M | $11.16M | $11.81M | $13.18M |
| Stockholders' Equity | $110.94M | $115.40M | $119.69M | $125.36M | $132.44M | $195.66M | $202.84M | $208.72M | $231.90M | $240.02M |
| Retained Earnings | ($304.31M) | ($299.77M) | ($295.24M) | ($289.12M) | ($281.72M) | ($217.91M) | ($210.72M) | ($204.02M) | ($180.09M) | ($170.93M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.26M) | - | - | - | ($6.65M) | - | - | - | ($7.59M) | - |
| Investing Cash Flow | $5.62M | - | - | - | $8.41M | - | - | - | $5.63M | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | $60.0K | - | - | - | $280.0K | - | - | - | $2.33M | - |
| Free Cash Flow | ($5.32M) | - | - | - | ($6.93M) | - | - | - | ($9.93M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 62.3% | - | 67.2% | 67.0% | 67.8% | - | 72.3% | 71.1% | 65.7% | - |
| Operating margin | -55.7% | - | -81.6% | -115.4% | -993.0% | - | -106.3% | -408.9% | -165.9% | - |
| EBITDA margin | -49.8% | - | -75.4% | -108.1% | -985.0% | - | -100.4% | -403.1% | -160.5% | - |
| Net margin | -51.5% | - | -75.6% | -106.2% | -981.7% | - | -95.7% | -390.3% | -146.3% | - |
| Free cash flow margin | -60.4% | - | - | - | -106.6% | - | - | - | -158.5% | - |
| FCF / Net income | 1.17 | - | - | - | 0.11 | - | - | - | 1.08 | - |
| R&D / Revenue | 13.1% | - | 22.0% | 27.1% | 28.5% | - | 26.4% | 24.6% | 28.3% | - |
| SG&A / Revenue | 61.5% | - | 72.9% | 88.5% | 96.3% | - | 96.7% | 111.7% | 137.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -3.7% | - | -4.7% | -5.4% | -44.6% | - | -3.1% | -10.9% | -3.8% | - |
| Return on equity | -4.1% | - | -5.1% | -5.9% | -48.2% | - | -3.3% | -11.5% | -4.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.01 | 6.78 | 7.67 | 8.44 | 9.89 | 8.76 | 10.82 | 11.39 | 11.50 | 11.06 |
| Quick ratio | 6.33 | 6.19 | 7.02 | 7.74 | 9.16 | 8.22 | 10.15 | 10.68 | 10.87 | 10.49 |
| Cash ratio | 1.09 | 0.95 | 0.89 | 1.00 | 1.19 | 0.75 | 1.21 | 1.01 | 1.37 | 1.43 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | -116.3x | -404.3x | - | - |
| Equity multiplier | 1.10 | 1.10 | 1.09 | 1.09 | 1.08 | 1.06 | 1.06 | 1.05 | 1.05 | 1.05 |
| Liabilities / Assets | 0.09 | 0.09 | 0.09 | 0.08 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 |
| Efficiency | ||||||||||
| Asset turnover | 0.07 | - | 0.06 | 0.05 | 0.05 | - | 0.03 | 0.03 | 0.03 | - |
| Inventory turnover | 0.56 | - | 0.48 | 0.41 | 0.39 | - | 0.36 | 0.32 | 0.42 | - |
| Days sales outstanding | 184d | - | 142d | 120d | 88d | - | 92d | 82d | 96d | - |
| Days inventory outstanding | 647d | - | 758d | 901d | 934d | - | 1023d | 1136d | 861d | - |
| Days payable outstanding | 242d | - | 226d | 329d | 400d | - | 448d | 479d | - | - |
| Cash conversion cycle | 588d | - | 674d | 692d | 622d | - | 667d | 739d | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 35.4% | - | 15.7% | 13.6% | 3.8% | - | 10.2% | 1.8% | 14.2% | - |
| Revenue CAGR (3y) | 17.1% | - | 606.0% | 657.8% | 674.3% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 24.4% | - | 7.4% | 7.0% | 7.0% | - | 16.0% | 7.8% | 7.4% | - |
| Operating income growth (YoY) | 92.4% | - | 11.2% | 67.9% | -521.5% | - | -25.1% | -271.8% | -38.3% | - |
| Net income growth (YoY) | 92.9% | - | 8.6% | 69.1% | -596.6% | - | -1264.0% | -355.9% | -43.5% | - |
| EPS growth (YoY) | - | - | 0.0% | 58.3% | -677.8% | - | -900.0% | -380.0% | -28.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 23.3% | - | - | - | 30.2% | - | - | - | -127.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -16.2% | -41.0% | -41.0% | -39.9% | -42.9% | -18.5% | -22.2% | -19.6% | -11.8% | -10.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$32.03M totalTherapeutics$26.20M · 81.8%
Development Services$3.03M · 9.5%
Diagnostics$2.80M · 8.7%
Product / service
$4.90M totalConsumables Revenue$2.11M · 43.1%
Engineering Revenue$1.98M · 40.3%
Capital Revenue$687.0K · 14.0%
Product And Service Other$123.0K · 2.5%
Geographic
$32.03M totalUS$26.46M · 82.6%
Non Us$5.57M · 17.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Zomedica Corp. against the 5 most active filers in the same SIC group.